Ensartinib before surgery for ALK-positive lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests the drug ensartinib, given before surgery, for people with ALK-positive lung cancer. Taking ensartinib first might shrink the tumor and make surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your lung cancer is ALK-positive (a specific genetic marker).
- Your cancer is at stage II or III and can be removed with surgery (or may become removable).
- You either have already started ensartinib as a first treatment (before surgery) or are planning to start it for 6-12 weeks.
- You have not had other systemic cancer treatments besides ensartinib (for the main group).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a pill called ensartinib, given before surgery to people with ALK-positive lung cancer. The goal is to see if it helps shrink the tumor and improve the chance of successful surgery.
This trial tests whether taking a pill called ensartinib after surgery can help prevent early stage lung cancer from coming back. It is for people whose tumors have a specific gene change called ALK and who have high-risk features.
This real-world study looks at how ensartinib works in people with advanced ALK-positive non-small cell lung cancer (NSCLC) whose disease has continued or worsened after ALK-targeted therapy. It may help doctors understand how well the treatment works and who benefits most in everyday care.
This trial tests a pill called ensartinib after you finish chemotherapy and radiation for stage III ALK-positive lung cancer. It may help keep the cancer from coming back.
This study looks at whether giving a targeted therapy pill (lorlatinib) before surgery can help shrink ALK-positive lung cancer and improve outcomes. It also aims to understand why some tumors may not respond to this treatment.
This trial tests the drug ensartinib to shrink lung cancer before surgery. It is for people with ALK-positive lung cancer that can be surgically removed.
Hear when a new Ensartinib trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.